Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PAR-101

Known as: PAR 101, PAR101 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Oral vancomycin and oral metronidazole have several limitations with regard to their use in the treatment of Clostridium… Expand
  • figure 1
  • table 2
Review
2014
Review
2014
OBJECTIVE To review the chemistry, pharmacology, microbiology, pharmacodynamics, pharmacokinetics, clinical efficacy… Expand
Review
2012
Review
2012
The two drugs currently recommended for the treatment of Clostridium difficile infection (CDI), namely vancomycin and… Expand
  • figure 1
  • table 1
Review
2012
Review
2012
Objective: To evaluate the pharmacology, microbiology, safety, and efficacy of fidaxomicin for treatment of Clostridium difficile… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2010
2010
ABSTRACT The effects of the inoculum, pH, cation concentrations, and different lots of commercial media on the in vitro… Expand
  • table 1
  • table 2
  • figure 1
Review
2010
Review
2010
  • Drugs in R&D
  • 2010
  • Corpus ID: 195684967
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum… Expand
Review
2010
Review
2010
Objective: To evaluate the efficacy and safety of fidaxomicin for the treatment of Clostridium difficile infection. Data Sources… Expand
  • figure 1
  • table 1
  • table 2
Review
2008
Review
2008
Background: Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and… Expand
Review
2008
Review
2008
BACKGROUND Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and… Expand
Review
2007
Review
2007
Clostridium difficile–associated disease (CDAD) has become an important public health problem. The causative organism is acquired… Expand